---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-002125"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:36:19.379542+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harrow closes $130M acquisition of five branded ophthalmic products from Novartis

## Summary
- Paid $130M at closing for U.S. rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, TRIESENCE; up to $45M milestone for Triesence.
- Funded with $59.75M senior secured loan, stock sale ($22.6M net), $40.25M 11.875% notes due 2027, and cash.
- Expects ~6-month transition; Novartis continues selling, transfers net profit to Harrow; NDAs to transfer.
- Reaffirms 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M; expects growth in 2024 and beyond.
- Products expected immediately accretive.

## SEC filing metadata
- accession: 0001493152-23-002125
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/0001493152-23-002125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-002125
- JSON: https://secwatch.observer/filing/0001493152-23-002125.json
- Plain text: https://secwatch.observer/filing/0001493152-23-002125.txt

## Key facts
- M&A Transactions
  HARROW, INC. completed an acquisition involving Novartis Technology, LLC and Novartis Innovative Therapies AG for $130,000,000 (closed 2023-01-20).
  - Action: acquisition
  - Counterparty: Novartis Technology, LLC and Novartis Innovative Therapies AG
  - Consideration: $130,000,000
  - Closing: 2023-01-20
  source text: suspension) 40 mg/ml. Under the terms of the Asset Purchase Agreement between the Company and Novartis (the “Purchase Agreement”), the Company made a one-time payment of $130,000,000 at closing, with up to another $45,000,000 due in a milestone payment related to the commercial availability of Triesence. Pursuant to the Purchase Agreement and various ancillary
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315223002125/0001493152-23-002125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.